139.6K XNAS Volume
XNAS 19 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 523,000 | 523,000 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Strategy Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 140,000 | 140,000 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 180,000 | 180,000 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2025 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 1,703,998 | 0 | - | - | Class A Common Stock | |
| Srinivas Akkaraju | Director | 01 Jul 2024 | 1,703,998 | 1,703,998 | - | - | Class A Common Stock | ||
| Srinivas Akkaraju | Director | 01 Jul 2024 | 1,703,998 | 0 | - | - | Series C Preferred Stock | ||
| Srinivas Akkaraju | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,703,998 | 1,703,998 | - | - | Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 14,973 | 14,973 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 30,642 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 30,642 | 30,642 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 53,475 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 206,074 | 206,074 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 206,074 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 53,475 | 53,475 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 175,401 | 0 | - | - | Class A Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 175,401 | 175,401 | - | - | Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 6,417 | 0 | - | - | Class A Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 6,417 | 6,417 | - | - | Common Stock | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 42,780 | 42,780 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 42,780 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 151,871 | 0 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 151,871 | 151,871 | - | - | Stock Option (Right to Buy) | |
| Roy Hardiman | Chief Business & Legal Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 14,973 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 171,122 | 171,122 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 42,780 | 42,780 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 42,780 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 2,994 | 2,994 | - | - | Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 2,994 | 0 | - | - | Class A Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 213,903 | 213,903 | - | - | Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 213,903 | 0 | - | - | Class A Common Stock | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 11,978 | 11,978 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 11,978 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 171,122 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 53,475 | 53,475 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 53,475 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 206,074 | 206,074 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 206,074 | 0 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 30,642 | 30,642 | - | - | Stock Option (Right to Buy) | |
| David M. Goldstein | Chief Scientific Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2024 | 30,642 | 0 | - | - | Stock Option (Right to Buy) | |
| Srinivas Akkaraju | Director | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 01 Jul 2024 | 1,562,500 | 3,266,498 | - | 16 | 25,000,000 | Common Stock |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 38,000 | 38,000 | - | - | Stock Option (Right to Buy) | |
| Patrick C. Machado | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 38,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,946 | 29,946 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 29,946 | 0 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 28,877 | 28,877 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 28,877 | 0 | - | - | Stock Option (Right to Buy) | |
| Sapna Srivastava | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 28,877 | 28,877 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 17,112 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 17,112 | 17,112 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 17,171 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 55,978 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 55,978 | 55,978 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 70,588 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 70,588 | 70,588 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 12,834 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 64,171 | 64,171 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 64,171 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 171,122 | 171,122 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 59,516 | 59,516 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 59,516 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 17,171 | 17,171 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 171,122 | 0 | - | - | Stock Option (Right to Buy) | |
| John R. Schroer | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 17,112 | 17,112 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 18,652 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 54,545 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 54,545 | 54,545 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 70,802 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 70,802 | 70,802 | - | - | Common Stock (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 64,171 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 64,171 | 64,171 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 5,347 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 5,347 | 5,347 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 85,561 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 85,561 | 85,561 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 171,122 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 171,122 | 171,122 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 0 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 12,834 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,652 | 18,652 | - | - | Stock Option (Right to Buy) | |
| Jorn Drappa | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 5,347 | 5,347 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 3,208 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 3,208 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 34,224 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 34,224 | 34,224 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 19,251 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 19,251 | 19,251 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 10,695 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 10,695 | 10,695 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 3,208 | 3,208 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 4,663 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 4,663 | 4,663 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 9,161 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 9,161 | 9,161 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 21,390 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 29,946 | 0 | - | - | Stock Option (Right to Buy) | |
| Derrick Richardson | SVP, People and Culture | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 29,946 | 29,946 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 534,759 | 534,759 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 534,759 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 106,951 | 106,951 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 106,951 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 380,852 | 380,852 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 380,852 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 21,390 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 21,390 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 90,804 | 90,804 | - | - | Common Stock | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 90,804 | 0 | - | - | Class A Common Stock | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 245,989 | 245,989 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 245,989 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 478,288 | 478,288 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 478,288 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 241,210 | 241,210 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 241,210 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 107,028 | 107,028 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 107,028 | 0 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 263,101 | 263,101 | - | - | Stock Option (Right to Buy) | |
| Martin Babler | Director, President, CEO and Chairman | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 263,101 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 20,026 | 0 | - | - | Class A Common Stock | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 21,978 | 0 | - | - | Class A Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,978 | 21,978 | - | - | Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 20,026 | 20,026 | - | - | Common Stock | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 20,026 | 0 | - | - | Class A Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 20,026 | 20,026 | - | - | Common Stock | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 4,278 | 4,278 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 4,278 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 4,278 | 4,278 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 130,481 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 130,481 | 130,481 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 128,342 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 128,342 | 128,342 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 12,834 | 12,834 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 23,093 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 23,093 | 23,093 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 155,304 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 155,304 | 155,304 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 53,475 | 0 | - | - | Stock Option (Right to Buy) | |
| Mark Bradley | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 53,475 | 53,475 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 73,155 | 73,155 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 42,780 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 42,780 | 42,780 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 21,390 | 21,390 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 11,842 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 11,842 | 11,842 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 79,572 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 79,572 | 79,572 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 38,502 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 38,502 | 38,502 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 33,796 | 0 | - | - | Class A Common Stock | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 33,796 | 33,796 | - | - | Common Stock | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 8,556 | 8,556 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 8,556 | 0 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 8,556 | 8,556 | - | - | Stock Option (Right to Buy) | |
| Sara Klein | General Counsel - Corp Secy | Sale or transfer of securities back to the company at price $ 0.00 per share. | 27 Jun 2024 | 73,155 | 0 | - | - | Stock Option (Right to Buy) |